- Data Adds to Opportunities For Intervention in the Interplay Between Diabetes and Cardiovascular Disease -
WHAT: The study, "Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients with Type 2 Diabetes and Dyslipidemia," conducted by Ronald B. Goldberg, M.D., chief of the Division of Diabetes and Metabolism, University of Miami, and presented as a late-breaker at this year's Scientific Sessions of the American Heart Association, is the largest head to head study to directly compare two insulin-sensitizing medications, ACTOS and Avandia. The study looks at the two agents' effects on lipids, including triglycerides, HDL-C and LDL-C levels, in people with diabetes.
WHY: It is common knowledge that people with diabetes have an increased risk of cardiovascular events such as heart attack. In fact, their risk is on par with people who have already suffered a heart attack. But data continues to accrue about the compelling confluence of various cardiovascular risk factors, such as diabetes, hypertension and dyslipidemia. The results of this study may suggest that physicians should look beyond the glycemic effects of these drugs to their potential lipid-altering effects in people with type 2 diabetes.
************** INTERVIEW OPPORTUNITIES AVAILABLE****************
WHO:
Ronald B. Goldberg, M.D., Professor of Medicine, Associate Director of the Diabetes Research Institute, Director, Lipid Disorder Clinic, University of Miami
WHEN/WHERE:
AHA Press Briefing: Wednesday, November 10, 7:30 to 8:30 a.m. CST, Location TBD
Data Presentation: Wednesday, November 10, 11:45 to 12:00 p.m. CST, Location TBD
CONTACTS:
Amy Losak, Ketchum, 646-935-3917, 917-865-6688, amy.losak@ketchum.com
Emily Nerad, Ketchum, 646-935-4166, 917-547-8728, emily.nerad@ketchum.com